论文部分内容阅读
目的:探讨联合血清HER2和VEGF水平在乳腺癌早期诊断的临床意义。方法:本研究共收集101例血清,其中乳腺癌患者36例,乳腺良性疾病患者35例,健康女性30例。应用ELISA定量检测血清HER2和VEGF水平。结果:乳腺癌患者血清HER2和VEGF水平均高于健康女性及乳腺良性肿瘤患者(P<0.05);乳腺良性疾病组与正常对照组结果比较差别无统计学意义(P>0.05);乳腺癌淋巴结转移组血清HER2和VEGF水平显著高于乳腺癌无淋巴结转移组(P<0.05);HER2与VEGF在乳腺癌血清中的表达呈显著正相关。结论:检测血清HER2和VEGF水平的变化对乳腺癌的早期诊断、良恶性肿瘤鉴别、有无淋巴结转移及预后评估均有重要的临床价值。
Objective: To investigate the clinical significance of combined serum levels of HER2 and VEGF in the early diagnosis of breast cancer. Methods: A total of 101 serum samples were collected in this study, including 36 cases of breast cancer, 35 cases of benign breast disease and 30 healthy women. Serum HER2 and VEGF levels were measured by ELISA. Results: The levels of serum HER2 and VEGF in patients with breast cancer were significantly higher than those in healthy women and benign breast tumors (P <0.05). There was no significant difference between benign breast disease patients and normal controls (P> 0.05) The levels of serum HER2 and VEGF in the metastatic group were significantly higher than those in the non-lymph node metastasis group (P <0.05). There was a significant positive correlation between the expression of HER2 and VEGF in the serum of breast cancer. Conclusion: The changes of serum HER2 and VEGF levels have important clinical value in early diagnosis of breast cancer, differentiation of benign and malignant tumors, lymph node metastasis and prognosis.